Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
A diagnosis of pancreatic cancer is devastating owing to its poor prognosis, with a 5-year survival rate of only 9%. Currently, most individuals are diagnosed at a late stage when treatment options are limited. Early detection of pancreatic cancer provides the greatest hope for making substantial improvements in survival. The Kenner Family Research Fund in partnership with the American Pancreatic Association has sponsored a series of fora to stimulate discussion and collaboration on early detection of pancreatic cancer. At the first forum in 2014, “Early Detection of Sporadic Pancreatic Cancer Summit Conference,” a strategic plan was set forth by an international group of interdisciplinary scientific representatives and subsequently The Strategic Map for Innovation was generated. The current conference report is the third forum in the series, “Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers,” which was held in Boston, Massachusetts, on October 27, 2016. This report provides an overview of examples of innovative initiatives by industry and confirms the critical need for collaboration among industry, government, research institutions, and advocacy groups in order to make pancreatic cancer more easily detectable in its earlier stages, when it is more treatable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because the baseline risk of PDAC even in subjects older than 50 years is very low, a 3-step (DEF) approach to its early detection has been suggested6: (1) Define a high-risk group for pancreatic cancer, (2) Enrich the high-risk group further to define a very high-risk group for pancreatic cancer, and (3) Find the lesion in the very high-risk cohort (Fig. 6).”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · cited 1×
“Pancreatic cancer is on track to become the second leading cause of cancer-related deaths in the United States by 2030.(1) A patient diagnosed with pancreatic cancer has a 5-year relative survival rate of 9%.”
BackgroundPhases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686 · cited 2×
“The Early Detection Research Network has developed and implemented systematic, comprehensive guidelines to develop, evaluate, and validate biomarkers, with rigor and reproducibility important for the scientific data.(9,10) This 5-phase approach establishes both a standard and a roadmap for successfully translating res…”
MethodPepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M., & Potter, J. D. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn326 · Cited by 717 · cited 2×
“The Early Detection Research Network has developed and implemented systematic, comprehensive guidelines to develop, evaluate, and validate biomarkers, with rigor and reproducibility important for the scientific data.(9,10) This 5-phase approach establishes both a standard and a roadmap for successfully translating res…”
MethodNew-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
Pannala, R., Basu, A., Petersen, G. M., & Chari, S. T. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70337-1 · Cited by 558 · cited 1×
“Currently, the only identified high-risk group for sporadic pancreatic cancer includes individuals with new-onset diabetes mellitus.(4) Approximately 20% to 25% of people with pancreatic cancer develop diabetes within 6 to 36months before their pancreatic cancer is diagnosed.”
BackgroundSelf-citationPrecision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Borrebaeck, C. A. K. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.153 · Cited by 435
Early Detection of Sporadic Pancreatic Cancer: Summative Review
Chari, S. T., Kelly, K., Hollingsworth, M. A., Thayer, S. P., Ahlquist, D. A., Andersen, D. K., Batra, S. K., Brentnall, T. A., Canto, M., Cleeter, D. F., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000368 · Cited by 295
Self-citationNew-onset diabetes in pancreatic cancer: A study in the primary care setting
Aggarwal, G., Rabe, K. G., Petersen, G. M., & Chari, S. T. (2012) · Pancreatology · doi:10.1016/j.pan.2012.02.003 · Cited by 90 · cited 1×
“Approximately 20% to 25% of people with pancreatic cancer develop diabetes within 6 to 36months before their pancreatic cancer is diagnosed.(5) With early detection, survival rate can increase 6-fold.”
BackgroundSelf-citationKenner, B. J., Chari, S. T., Maitra, A., Srivastava, S., Cleeter, D. F., Go, V. L. W., Rothschild, L. J., & Goldberg, A. E. (2016) · Pancreas · doi:10.1097/mpa.0000000000000701 · Cited by 67
Self-citationEarly Detection of Sporadic Pancreatic Cancer: Strategic Map for Innovation—A White Paper
Kenner, B. J., Chari, S. T., Cleeter, D. F., & Go, V. L. W. (2015) · Pancreas · doi:10.1097/mpa.0000000000000369 · Cited by 56 · cited 1×
“With early detection, survival rate can increase 6-fold.(6) Hence, the need for noninvasive, discriminatory biomarkers for early detection is urgent.”
BackgroundSelf-citation
Cited by
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Self-citationPhyo, J. B., Woo, A., Yu, H. J., Lim, K., Cho, B. H., Jung, H. S., & Lee, M. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04200 · Cited by 107
Early Diagnosis of Pancreatic Cancer: The Key for Survival
Gheorghe, G., Bungau, S., Ilie, M., Behl, T., Vesa, C. M., Brisc, C., Bacalbasa, N., Turi, V., Costache, R. S., & Diaconu, C. C. (2020) · Diagnostics · doi:10.3390/diagnostics10110869 · Cited by 100
“The disease is characterized by late-onset symptoms, rapid progression, and death [8].”
BackgroundDevelopments in diagnostic applications of saliva in human organ diseases
Cui, Y., Yang, M., Zhu, J., Hangkun, Z., Duan, Z., Wang, S., Liao, Z., & Liu, W. (2022) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2022.100115 · Cited by 113
Clinical application of quantitative glycomics
Peng, W., Zhao, J., Dong, X., Banazadeh, A., Huang, Y., Hussien, A. A., & Mechref, Y. S. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1543594 · Cited by 55
“The clinical management of pancreatic cancer is hampered by the rapid progression and large portion of asymptomatic individuals at an early stage of the disease [131].”
Background
Metadata
- Authors
- Kenner, B. J., Go, V. L. W., Chari, S. T., Goldberg, A. E., & Rothschild, L. J.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Kenner, Barbara J.
- Goldberg, Ann E.
- Rothschild, Laura J.
- Venue
- Pancreas
- Published
- 2017-11
- Volume
- 46
- Issue
- 10
- Pages
- 1238-1241
- ISSN
- 0885-3177 (ISSN-L)
- 1536-4828
- PMC
- PMC5647107
- OpenAlex
- W2759631471
- Semantic Scholar
- acd0dcf6cca44c7f711dcf44801e6fe477e5d667
- Cited by
- 24
- References
- 12
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 5
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Pancreas (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Division of Cancer Prevention, National Cancer Institute
- Cedars-Sinai Medical Center
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic cancer, early detection, biomarkers, industry partnerships, strategic planning, interdisciplinary collaboration, cancer screening
- MeSH terms
- Congresses as Topic, Cooperative Behavior, Diffusion of Innovation, Drug Industry, Humans, International Cooperation, Pancreatic Neoplasms, Biomarkers, Tumor, Molecular Diagnostic Techniques, Biomedical Research, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers. https://app.cochat.ai/papers/10.1097/mpa.0000000000000939
- The paper
- Kenner, B. J., Go, V. L. W., Chari, S. T., Goldberg, A. E., & Rothschild, L. J. (2017). Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers. Pancreas. https://doi.org/10.1097/mpa.0000000000000939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

